These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19276280)

  • 1. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
    Nair JS; de Stanchina E; Schwartz GK
    Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Walsby E; Walsh V; Pepper C; Burnett A; Mills K
    Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
    Tomita M; Tanaka Y; Mori N
    Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
    Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
    Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
    Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
    Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
    Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
    Tao Y; Leteur C; Calderaro J; Girdler F; Zhang P; Frascogna V; Varna M; Opolon P; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Cell Cycle; 2009 Oct; 8(19):3172-81. PubMed ID: 19755861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
    Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
    Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.
    Ma Y; Weimer J; Fredrik R; Adam-Klages S; Sebens S; Caliebe A; Hilpert F; Eckmann-Scholz C; Arnold N; Schem C
    Arch Gynecol Obstet; 2013 Jul; 288(1):173-82. PubMed ID: 23389245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of aurora kinase B inhibitor AZD1152 in the treatment of cisplatin-resistant ovarian carcinoma].
    Ma YX; Li XZ
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jan; 48(1):46-50. PubMed ID: 23531251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
    Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.
    Zekri A; Ghaffari SH; Ghanizadeh-Vesali S; Yaghmaie M; Salmaninejad A; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
    Tumour Biol; 2015 Feb; 36(2):623-32. PubMed ID: 25277659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.